Published in Clin Chem on October 01, 1983
Convulsions associated with cyclosporin A. Br Med J (Clin Res Ed) (1985) 1.04
Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography. Transplant Proc (1986) 0.82
The influence of haematocrit on blood cyclosporin measurements in vivo. Br J Clin Pharmacol (1988) 0.76
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J (2003) 3.78
Fission and uncoating of synaptic clathrin-coated vesicles are perturbed by disruption of interactions with the SH3 domain of endophilin. Neuron (2000) 2.80
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J (2002) 2.68
Procedural complications of central venous catheter insertion. Minerva Anestesiol (2012) 2.67
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay (1981) 2.55
Fine structure of the gradient of polarity in the z gene of the lac operon of Escherichia coli. J Mol Biol (1970) 2.43
One-year mortality among unselected outpatients with heart failure. Eur Heart J (2002) 2.30
Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet (1985) 2.01
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol (1990) 1.76
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther (1983) 1.73
Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol (1997) 1.62
Continuous spinal anesthesia versus continuous femoral nerve block for elective total knee replacement. Minerva Anestesiol (2011) 1.48
It is not the epidural that is dangerous, but the person who gives it. Br J Anaesth (2014) 1.43
Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest (1999) 1.40
Cyclosporin A: correlation between HPLC and RIA serum levels. Pharm Weekbl Sci (1982) 1.32
Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart (1999) 1.26
Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline. Am Rev Respir Dis (1982) 1.18
Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol (1995) 1.16
Multicompartment pharmacokinetics of netilmicin. Eur J Clin Pharmacol (1979) 1.16
Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol (1995) 1.12
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Drug-induced pulmonary hypertension? Br Med J (1971) 1.12
Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation (2001) 1.10
Influence of chronic dosing on theophylline clearance. Br J Clin Pharmacol (1985) 1.07
Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother (2000) 1.07
Population pharmacokinetics of tobramycin. Br J Clin Pharmacol (1989) 1.07
Ingested asbestos and intestinal carcinogenesis in F344 rats. J Environ Pathol Toxicol (1981) 1.03
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation (1995) 1.02
Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol (1986) 1.01
Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet (1983) 1.00
Network "Rodent-borne pathogens" in Germany: longitudinal studies on the geographical distribution and prevalence of hantavirus infections. Parasitol Res (2008) 0.98
Predicting individual phenytoin dosage. J Pharmacokinet Biopharm (1981) 0.98
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol (1986) 0.96
Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol (1992) 0.95
Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother (1981) 0.95
Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol (1995) 0.95
Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance. Br J Clin Pharmacol (1979) 0.94
Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS). Eur J Clin Pharmacol (1984) 0.94
Sensitivity to two-stage carcinogenesis of SENCAR mouse skin grafted to nude mice. Cancer Res (1982) 0.93
A comparison of cardiovascular effects of dobutamine and isoprenaline after open heart surgery. Br Heart J (1976) 0.93
Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation (1994) 0.93
Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol (1992) 0.92
Population pharmacokinetics of quinidine. Br J Clin Pharmacol (1991) 0.92
Spontaneous multivessel coronary artery dissection in a pregnant woman treated successfully with stent implantation. Am J Med (1999) 0.91
[Aortic valve insufficiency in Crohn disease]. Schweiz Med Wochenschr (1997) 0.91
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol (1987) 0.91
Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol (2001) 0.90
Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol (1996) 0.90
Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol (1982) 0.89
Cardiovascular effects of a new inotropic drug in dog and normal man. Clin Pharmacol Ther (1976) 0.89
Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab (1998) 0.89
Once a day verapamil in essential hypertension. Br J Clin Pharmacol (1986) 0.88
Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol (1988) 0.88
Influence of thyroid function on theophylline kinetics. Clin Pharmacol Ther (1984) 0.88
Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis (1996) 0.88
Primary angiosarcoma of the pulmonary arteries: dynamic contrast-enhanced MRI. J Comput Assist Tomogr (1998) 0.87
Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. Ann Oncol (1996) 0.87
Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation grade 2) early and late after transplantation. Circulation (1996) 0.87
Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J (1999) 0.86
Performance of Bayesian feedback to forecast lidocaine serum concentration: evaluation of the prediction error and the prediction interval. J Pharmacokinet Biopharm (1985) 0.86
Shifts in auditory brainstem response latencies following plasma-level-controlled aminoglycoside therapy. Eur Arch Otorhinolaryngol (1990) 0.86
Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol (1986) 0.86
A foam-cushion face mask and a see-through operation table: a new set-up for face protection and increased safety in prone position. Br J Anaesth (2007) 0.86
Determination of saquinavir in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 0.86
Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr (1983) 0.85
[On evaluation of the thoracic picture in acute pulmonary embolism]. Schweiz Med Wochenschr (1968) 0.85
Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem (1988) 0.85
Changes in the QRS complex after aortic valve replacement. Br Heart J (1972) 0.85
Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol (1982) 0.85
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol (1990) 0.85
Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. J Pharmacol Exp Ther (1999) 0.85
N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther (1996) 0.84
In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol (1995) 0.84
Induction of thyroid lesions in 14-week toxicity studies of 2 and 4-methylimidazole in Fischer 344/N rats and B6C3F1 mice. Arch Toxicol (2005) 0.84
Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ther Drug Monit (1995) 0.83
Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther (1985) 0.83
Determination of dextromethorphan and dextrorphan in urine by high-performance liquid chromatography after solid-phase extraction. J Pharm Biomed Anal (1991) 0.83
Unusual electrocardiographic changes in Ebstein's anomaly. Br Heart J (1972) 0.83
Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. Am J Cardiol (1999) 0.83
Captopril and systemic lupus erythematosus syndrome. BMJ (1990) 0.83
Amiodarone inhibits arterial thrombus formation and tissue factor translation. Arterioscler Thromb Vasc Biol (2008) 0.83
Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. Heart (1999) 0.83
Ruptured ventricular pseudoaneurysm. Heart (1998) 0.82
Rapid prediction of individual dosage requirements for lignocaine. Clin Pharmacokinet (1984) 0.82